Submit a Review & Earn an Amazon Gift Card
You can now submit reviews for your favorite Tocris products. Your review will help other researchers decide on the best products for their research. Why not submit a review today?!
Submit Review(R)-MCPG
Discontinued Product
0338 has been discontinued.
View all Non-selective Metabotropic Glutamate products.
说明： Relatively inactive isomer of (0336)
化学名： (R)-a-Methyl-4-carboxyphenylglycine
生物活性 for (R)-MCPG
Relatively inactive isomer of (RS)-MCPG (0336). Non-selective group I/group II metabotropic glutamate receptor antagonist.
技术数据 for (R)-MCPG
| 分子量 | 209.2 |
| 储存 | Store at RT |
| CAS Number | 150145-89-4 |
上方提供的技术数据仅供参考。批次相关数据请参见分析证书。
Tocris products are intended for laboratory research use only, unless stated otherwise.
产品说明书 for (R)-MCPG
分析证书目前不在网上提供。
请联系客户服务
请联系客户服务
参考文献 for (R)-MCPG
参考文献是支持产品生物活性的出版物。
Jane et al (1993) Stereospecific antagonism by (+)-α-methyl-4-carboxyphenylglycine (MCPG) of 1S,3R-ACPD induced effects in neonatal rat motoneurones and rat thalamic neurones. Neuropharmacology 32 725 PMID: 7689710
关键词: (R)-MCPG, (R)-MCPG supplier, Non-selective, mGlu, 0338, Tocris Bioscience
(R)-MCPG 的评论
目前没有该产品的评论。 Be the first to review (R)-MCPG and earn rewards!
Have you used (R)-MCPG?
Submit a review and receive an Amazon gift card.
$25/€18/£15/$25CAN/¥75 Yuan/¥2500 Yen for a review with an image
$10/€7/£6/$10 CAD/¥70 Yuan/¥1110 Yen for a review without an image
该领域的文献
Tocris offers the following scientific literature in this area to showcase our products. We invite you to request* your copy today!
*请注意，Tocris 仅会向正规科研企业/机构地址发送文献。
Metabotropic Glutamate Receptors Scientific Review
Written by Francine Acher, this review discusses the pharmacology and therapeutic potential of mGlu receptors, and the compounds acting upon them; compounds available from Tocris are listed.
Parkinson's Disease Poster
Parkinson's disease (PD) causes chronic disability and is the second most common neurodegenerative condition. This poster outlines the neurobiology of the disease, as well as highlighting current therapeutic treatments for symptomatic PD, and emerging therapeutic strategies to delay PD onset and progression.